Progress worth following.
Follow GenLumina’s scientific validation, company milestones, partnerships and funding progress as we advance light-activated precision oncology.
From evidence to impact.
Research results, development milestones and the people and organisations helping GenLumina move the platform forward.
Targeting therapy for breastcancer
Validation of our new targeting therapy (ADC) for breastcancer in preclinical phase
Annual Report 2025
Our first annual report – the foundation
The last mile in precision oncology (CRIG)
controlled activation
Kansen voor West
Medegefinancierd door de Europese Unie
IP granted by Netherlands Patent Office
GenLumina Secures Patent Grant in the Netherlands for Its Light-Activated Nanomedicine Platform.
New Step in Targeted Cancer Therapy
Dutch subsidy for key research on colorectal cancer with LUMC.
Genlumina Awarded MIT Grant for ‘Silver Bullet’ Feasibility Study
Genlumina has received a grant from the Province of South Holland
UNIIQ invests in GenLumina
We got strategic funding from UNIIQ as spinout of University Leiden.
GenLumina among the 40 Most Promising Startup 2025
Our future market is Europa, Japan and US. If we make to the top 10 startups, we get to explore the market in US in this early stage!
Genlumina Founded in Leiden: Pioneering Cancer Treatment with Light-Activated Drugs
Learn how Genlumina, founded in Leiden on August 13, 2024, is using light-activated treatments to bring new possibilities to cancer care.
Follow the journey from preclinical evidence to patient impact.
Connect with GenLumina for scientific collaboration, pharmaceutical partnering, investment or company updates.